Navigation Links
EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022
Date:4/22/2013

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022
http://www.reportlinker.com/p01163173/EpiCast-Report-Cystic-Fibrosis---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022

Summary

Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the US and more than 35,000 cases in the European Union (EU) (Cystic Fibrosis Foundation Patient Registry, 2011; Farrell, 2008). CF causes abnormally thick, sticky mucus to accumulate in the respiratory, digestive, and reproductive systems. It is one of the most common chronic lung diseases and is widespread throughout the world. The specific defective gene that cases CF is the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries. GlobalData forecasts that the US and UK will have the most prevalent cases of CF in 2022. In 2022, the combined prevalent CF cases in the 5EU countries (France, Germany, Italy, Spain, and the UK) will be slightly larger than the number of prevalent CF cases in the US. The UK and France will have the greatest prevalence proportions (0.0157% and 0.0097%, respectively) and the largest 10-year growth (33.2% and 38.1%, respectively), implying that this may be the result of a higher prevalence of CF gene mutations in these populations. The high number of prevalent cases of CF in the US is due to all 50 states screening for CF in newborns. National CF screenings are imperative in detecting and capturing the true prevalence of the disease in a given country.

Scope

- The Cystic Fibrosis EpiCast Report provides an overview of the risk factors and comorbidities associated with cystic fibrosis, as well as global trends in prevalence in the six major markets (the US, France, Germany, Italy, Spain, and the UK).
- It also includes a 10-year epidemiological forecast of prevalent cases of cystic fibrosis segmented by sex, age (segmented by five-year age groups, beginning at age 0 years and ending at ages 35 years and older), and mutation type (F508del, G551D, G54X, W1282X, 621+1G>1, R553X, and 3950delT).

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global cystic fibrosis market.
- Quantify patient populations in the global cystic fibrosis market to improve product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying sex and age groups that present the best opportunities for cystic fibrosis therapeutics in each of the markets covered.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Risk Factors and Comorbidities 8
3.1.1 The occurrence of cystic fibrosis is approximately one in 2,500 Caucasians 9
3.1.2 Increased cystic fibrosis life expectancy increases comorbidities of CF-related diabetes and bone disease 9
3.2 Global Trends 10
3.2.1 United States 10
3.2.2 France 11
3.2.3 Germany 11
3.2.4 Italy 12
3.2.5 Spain 12
3.2.6 United Kingdom 13
3.3 Forecast Methodology 13
3.3.1 Sources Used 13
3.3.2 Forecast Assumptions and Methods 16
3.3.3 Sources Not Used 19
3.4 Epidemiology Forecast 19
3.4.1 Total Prevalent Cases of Cystic Fibrosis 19
3.4.2 Total Prevalent Cases of Cystic Fibrosis Segmented by Age 21
3.4.3 Total Prevalent Cases of Cystic Fibrosis Segmented by Sex 22
3.4.4 Total Prevalent Cases of Cystic Fibrosis by Mutation Type 23
3.5 Discussion 25
3.5.1 Conclusion on Epidemiology Trends 25
3.5.2 Limitations of the Analysis 25
3.5.3 Strengths of the Analysis 25
4 Appendix 26
4.1 Bibliography 26
4.2 About the Authors 31
4.2.1 Epidemiologists 31
4.2.2 Reviewers 31
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 33
4.2.4 Global Head of Healthcare 33
4.3 About GlobalData 34
4.4 About EpiCast 34
4.5 Contact Us 34
4.6 Disclaimer 35

List of Tables

Table 1: Six Major Markets, Sources of Cystic Fibrosis Prevalence Data 14
Table 2: Six Major Markets, Sources of Cystic Fibrosis-Causing Mutation Data 14
Table 3: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, Males and Females, Selected Years, 2012–2022 20
Table 4: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, By Sex, 2012 , N (%) 22
Table 5: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0–35 Years, Males and Females, 2012 23

List of Figures

Figure 1: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, Males and Females, Selected Years, 2012–2022 20
Figure 2: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, By Age, Males and Females, 2012 21
Figure 3: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0–35 Years, Males and Females, 2012 24

To order this report:
Pathology Industry: EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022

__________________________
Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Report: Drugstore Networks Could Save Employers, Medicare, and Medicaid $115 Billion
2. Home Affairs Committees Drugs Report: Angelus Foundation Says the Prime Minister Should Not Have Rejected a Royal Commission
3. Report: Independent Drugstores, Policymakers Face New Challenges
4. Pharma IQs Laboratory Informatics Report: Current Trends & Predictions for 2015
5. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
6. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
7. N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
8. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
9. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
10. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
11. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... NEW YORK , Dec. 6, 2016 ... atomic nucleus. Radioisotopes are produced either by using nuclear ... energy in the form of alpha, beta or gamma ... thus emitted are used in Nuclear medicine, specifically in ... to provide diagnostic information about a human body,s functioning. ...
(Date:12/6/2016)... 6, 2016 Human Vaccines Market: Scope ... wise and country wise analysis of the human ... of human vaccines products, raw material suppliers, vaccine ... the market. The report provides qualitative and ... Qualitative analysis comprises market dynamics, trends, product overview, ...
(Date:12/6/2016)... BOLTON, Miss. , Dec. 6, 2016 ... and rescue personnel in a simulated mass casualty event ... Mississippi . The technology debuted before an audience ... Bryant and representatives from Homeland Security, Federal Law ... Telemedical Drone Project, known as HiRO (Health Integrated Rescue ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... “Tomorrow Trump Goes ... Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes To ... do as much as she can for this country. , Nancy attributes her patriotic ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men ... a higher risk of serious health problems, such as cardiovascular illness, according to ... Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the correlation ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health management, announces today a strategic relationship with CitiusTech, a leading healthcare ... engine that offers advanced Clinical Quality Measures (CQM) computation capabilities (as a ...
(Date:12/6/2016)... ... December 06, 2016 , ... CarriersEdge, providers of online ... new suite of Driver Wellness courses. Offered in three modules, the courses can be ... so fleets can educate drivers about how to stay healthy on the road. , ...
Breaking Medicine News(10 mins):